Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
Pharma CEO Martin Schkreli is Arrested For Fraud
***
***
Conclusion
Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.
Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com
OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:
- PRACTICES: www.BusinessofMedicalPractice.com
- HOSPITALS: http://www.crcpress.com/product/isbn/9781466558731
- CLINICS: http://www.crcpress.com/product/isbn/9781439879900
- ADVISORS: www.CertifiedMedicalPlanner.org
- FINANCE: Financial Planning for Physicians and Advisors
- INSURANCE: Risk Management and Insurance Strategies for Physicians and Advisors
- Dictionary of Health Economics and Finance
- Dictionary of Health Information Technology and Security
- Dictionary of Health Insurance and Managed Care
Share this:
Filed under: Drugs and Pharma, Ethics | Tagged: Leo Varadkar, Martin Schkreli |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Physician Payments from Manufacturers Released
The Physician Payments Sunshine Act, passed under the Affordable Care Act, requires all pharmaceutical and medical device companies to report payments to physicians, including consulting fees, gifts, speaking fees, meals, travel, and research grants. This information is searchable to the public on a database called Open Payments, managed by the Centers for Medicare & Medical Services (CMS). A recent study by researchers at University of California, San Diego School of Medicine analyzed this database and compared payments among different specialties and identified which ones topped the list. The study was published online the week of January 4 by Mayo Clinic Proceedings.
Researchers scrutinized 2.4 million physician payments totaling $475 million made during the last five months of 2013. Internal medicine and orthopedic surgery received the greatest total value at $111 million each. By plugging in the first and last name of a physician on the Open Payments site, an individual can see industry payments listed by company, nature of payment, date, and amount.
Source: Michelle Brubaker, UC San Diego Health [1/4/16]
LikeLike
Pharma Companies Paid 618,000 Physicians $2 Billion in 2015
ProPublica recently released updated statistics for their Dollars for Docs database on pharmaceutical industry payments to US physicians. Here are some key findings from the report:
• From 2013-2015, companies paid $600 million a year to teaching hospitals.
• Companies made $2 billion in general payments to 618,000 physicians each year.
• 1 in 4 doctors who received a payment in 2015 didn’t receive one in 2014.
• Blood thinner Xarelto ($28.4 million) was the top payer to physicians in 2015.
• Arthritis drug Humira made $24.9 million in payments to physicians in 2015.
• Diabetes drug Invokana made $20.9 million in payments to physicians in 2015.
Source: ProPublica, December 13, 2016
LikeLike
“Report: Drug company faked cancer patients to sell drug –
“When Insys Therapeutics got approval to sell an ultra-powerful opioid for cancer patients with acute pain in 2012, it soon discovered a problem: finding enough cancer patients to use the drug. To boost sales, the company allegedly took patients who didn’t have cancer and made it look like they did.“
http://www.cnn.com/2017/09/06/politics/insys-cancer-drug-company-faked-cancer-patients-to-sell-drug/index.html
Aaron M. Kessler for CNN
[September 6, 2017]
LikeLike